Effectiveness of Different Doses of Liposomal Bupivacaine in Nerve Block for Pain Relief After Robotic Total Knee Replacement Surgery

What this Trial Is About

Total knee arthroplasty TKA is a common surgery for severe osteoarthritis when other treatments do not work. However, many patients experience significant pain after surgery, which can slow recovery and increase opioid use. Researchers are studying different doses of liposomal bupivacaine in the adductor canal block, a pain relief technique, to see how it affects pain and opioid use after robotic-assisted TKA. This is a randomized controlled trial sponsored by The University of Hong Kong. Participants will receive one of three treatments during surgery an adductor canal block with standard bupivacaine, a combination of liposomal and standard bupivacaine, or liposomal bupivacaine alone in different doses. The study will compare the effects of these doses on pain relief and opioid consumption. The trial uses a triple-blind method and includes detailed monitoring of drug levels, pain scores, and recovery measures. During the study, participants will have their pain levels measured frequently for up to 7 days after surgery, along with assessments of knee function, opioid side effects, and quality of recovery. Blood samples will be taken to check bupivacaine levels. Long-term outcomes such as chronic pain, knee function, and quality of life will be evaluated at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome is the overall pain score at rest during the first 48 hours after surgery.

Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty